Searched for
ZYDUS WELLNESS SHARES
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- Parag Parikh Flexi Cap Fund raises stake in ITC, HDFC Bank and 14 other stocks in MayParag Parikh Flexi Cap Fund, India’s largest active flexi-cap scheme by AUM, raised exposure to ITC, HDFC Bank and 14 other stocks in May, ...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Zydus Lifesciences, 2 other share buybacks closing today. Are you participating?Investors have a final opportunity to tender shares in buyback offers from Zydus Lifesciences, Dhanuka Agritech, and CyberTech Systems and ...
- Sooryavanshi’s catch! Brands set tight field as endorsement race heats up after IPL breakoutThe spotlight shines brightly on young cricketer Vaibhav Sooryavanshi, who is rapidly becoming a sought-after name in the sports world. Cor...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Bond yields, FIIs and corporate actions among 8 factors to steer D-Street this weekNifty closed marginally higher last week, driven by IT and energy stocks, as markets brace for key events. Technical analysts suggest Nifty...
- Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the J...
- Bayer bets big on 'self-care' market to deepen India playGlobal pharma major Bayer is significantly expanding its consumer healthcare presence in India, targeting the burgeoning self-care market e...
- Zydus Lifesciences to pursue acquisitions in specialty, rare diseasesZydus Lifesciences is set to acquire US firm Assertio Holdings for $166.40 million. This move aims to build a strong specialty oncology bus...
- Zydus to buy Assertio for $166.4 millionZydus is acquiring US-based Assertio Holdings for $166.40 million to bolster its specialty oncology presence in the US. The deal, structure...
- Zydus Lifesciences acquires US pharma firm Assertio for $166 millionIn a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166...
- Parag Parikh Flexi Cap Fund increase stake ITC, TCS, HDFC Bank and 14 other stocks in AprilParag Parikh Flexi Cap Fund boosted its holdings in ITC, TCS, and HDFC Bank during April. The fund also increased its stake in fourteen oth...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Zydus Wellness 1:5 stock split: Shares start trading ex-split on ThursdayZydus Wellness shares will trade ex-split on exchanges. The face value reduces from Rs 10 to Rs 2. The record date is September 18, 2025. T...
- Add Zydus Wellness, target price Rs 2,000: ICICI SecuritiesICICI Securities has issued an 'add' recommendation on Zydus Wellness with a target price of Rs 2,000, up from the current Rs 1,779. Zydus,...
- Zydus Wellness shares rally nearly 4% after reporting PAT at Rs 150 crore; declares Rs 5 dividendZydus Wellness shares surged 3.8% on BSE, reaching a new 52-week high at Rs 1,750.20 following a 4% YoY rise in Q4 FY24 profit after tax to...
- Zydus shows resilience driven by improving FMCG footprintFor Zydus group, pharma had been the core business for over a decade, while the FMCG business remained on the back burner. However, its agg...
- Buy Zydus Wellness Ltd with a target of Rs 710: Ashwani Gujral"Zydus Wellness Ltd is a 'BUY' call with a target of Rs 7105 and a stop loss of Rs 640."
Load More
